Brain and systemic glucose metabolism in the healthy elderly following fish oil supplementation

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 85, Issue 5, 2011, Pages 287-291

  Nugent, S ^a   Croteau, E ^a,b   Pifferi, F ^a   Fortier, M ^a   Tremblay, S ^a,b   Turcotte, E ^a,b   Cunnane, S C ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; FISH OIL; FLUORODEOXYGLUCOSE F 18; ICOSAPENTAENOIC ACID; INSULIN; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ANTERIOR CINGULATE; ARTICLE; BRAIN METABOLISM; CEREBELLUM; CEREBRAL METABOLIC RATE OF GLUCOSE; COGNITION; CONTROLLED STUDY; DIET SUPPLEMENTATION; FAT INTAKE; FEMALE; FRONTAL LOBE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HIPPOCAMPUS; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; MALE; METABOLIC SYNDROME X; NERVOUS SYSTEM PARAMETERS; NORMAL HUMAN; OCCIPITAL LOBE; ORAL GLUCOSE TOLERANCE TEST; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; TEMPORAL LOBE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; AGING; CEREBELLUM; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 80053587368     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2011.04.008     Document Type: Article

References (33)

1. Cunnane S., Nugent S., Roy M., et al. Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition 2011, 27:3-20.
2. Cunnane S.C., Plourde M., Pifferi F., Begin M., Feart C., Barberger-Gateau P. Fish, docosahexaenoic acid and Alzheimer's disease. Prog. Lipid Res. 2009, 48:239-256.
3. Freemantle E., Vandal M., Tremblay-Mercier J., et al. Omega-3 fatty acids, energy substrates, and brain function during aging. Prostaglandins Leukotrienes Essent. Fatty Acids 2006, 75:213-220.
4. Sokoloff L., Reivich M., Kennedy C., et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem. 1977, 28:897-916.
5. Pifferi F., Roux F., Langelier B., et al. (n-3) polyunsaturated fatty acid deficiency reduces the expression of both isoforms of the brain glucose transporter GLUT1 in rats. J. Nutr. 2005, 135:2241-2246.
6. Ximenes da Silva A., Lavialle F., Gendrot G., Guesnet P., Alessandri J.M., Lavialle M. Glucose transport and utilization are altered in the brain of rats deficient in n-3 polyunsaturated fatty acids. J. Neurochem. 2002, 81:1328-1337.
7. Pifferi F., Jouin M., Alessandri J.M., et al. n-3 Fatty acids modulate brain glucose transport in endothelial cells of the blood-brain barrier. Prostaglandins Leukotrienes Essent. Fatty Acids 2007, 77:279-286.
8. Pifferi F., Jouin M., Alessandri J.M., et al. n-3 long-chain fatty acids and regulation of glucose transport in two models of rat brain endothelial cells. Neurochem. Int. 2010.
9. Nkondjock A., Shatenstein B., Ghadirian P. A case-control study of breast cancer and dietary intake of individual fatty acids and antioxidants in Montreal. Canada, Breast 2003, 12:128-135.
10. Vandal M., Freemantle E., Tremblay-Mercier J., et al. Plasma omega-3 fatty acid response to a fish oil supplement in the healthy elderly. Lipids 2008, 43:1085-1089.
11. Plourde M., Vohl M.C., Vandal M., Couture P., Lemieux S., Cunnane S.C. Plasma n-3 fatty acid response to an n-3 fatty acid supplement is modulated by apoE epsilon4 but not by the common PPAR-alpha L162V polymorphism in men. Br. J. Nutr. 2009, 102:1121-1124.
12. Croteau E., Lavallee E., Labbe S.M., et al. Image-derived input function in dynamic human PET/CT: methodology and validation with 11Cacetate and 18F-fluorothioheptadecanoic acid in muscle and 18F-fluorodeoxyglucose in brain. Eur. J. Nucl. Med. Mol. Imaging 2010.
13. Thie J.A. Understanding the standardized uptake value, its methods, and implications for usage. J. Nucl. Med. 2004, 45:1431-1434.
14. Loessner A., Alavi A., Lewandrowski K.U., Mozley D., Souder E., Gur R.E. Regional cerebral function determined by FDG-PET in healthy volunteers: normal patterns and changes with age. J. Nucl. Med. 1995, 36:1141-1149.
15. Ibanez V., Pietrini P., Alexander G.E., et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 1998, 50:1585-1593.
16. Reivich M., Alavi A., Wolf A., et al. Glucose metabolic rate kinetic model parameter determination in humans: the lumped constants and rate constants for [18F]fluorodeoxyglucose and [11C]deoxyglucose. J. Cereb. Blood Flow Metab. 1985, 5:179-192.
17. Graham M.M., Peterson L.M., Hayward R.M. Comparison of simplified quantitative analyses of FDG uptake. Nucl. Med. Biol. 2000, 27:647-655.
18. Huang S.C. Anatomy of SUV. Standardized uptake value. Nucl. Med. Biol. 2000, 27:643-646.
19. Sun F.T., Schriber R.A., Greenia J.M., He J., Gitcho A., Jagust W.J. Automated template-based PET region of interest analyses in the aging brain. Neuroimage 2007, 34:608-617.
20. Ibanez V., Pietrini P., Furey M.L., et al. Resting state brain glucose metabolism is not reduced in normotensive healthy men during aging, after correction for brain atrophy. Brain Res. Bull. 2004, 63:147-154.
21. Yanase D., Matsunari I., Yajima K., et al. Brain FDG PET study of normal aging in Japanese: effect of atrophy correction. Eur. J. Nucl. Med. Mol. Imaging 2005, 32:794-805.
22. Willis M.W., Ketter T.A., Kimbrell T.A., et al. Age, sex and laterality effects on cerebral glucose metabolism in healthy adults. Psychiatry Res. 2002, 114:23-37.
23. Schlyer D.J. PET tracers and radiochemistry. Ann. Acad. Med. Singapore 2004, 33:146-154.
24. Basu R., Breda E., Oberg A.L., et al. Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance. Diabetes 2003, 52:1738-1748.
25. Borkman M., Storlien L.H., Pan D.A., Jenkins A.B., Chisholm D.J., Campbell L.V. The relation between insulin sensitivity and the fatty-acid composition of skeletal-muscle phospholipids. N. Engl. J. Med. 1993, 328:238-244.
26. Keyes J.W. SUV: standard uptake or silly useless value?. J. Nucl. Med. 1995, 36:1836-1839.
27. Lee S., Choi S., Kim H.J., et al. Cutoff values of surrogate measures of insulin resistance for metabolic syndrome in Korean non-diabetic adults. J. Korean Med. Sci. 2006, 21:695-700.
28. Greenwood C.E., Winocur G. High-fat diets, insulin resistance and declining cognitive function. Neurobiol. Aging 2005, 26(Suppl 1):42-45.
29. Baker L.D., Cross D.J., Minoshima S., et al. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch. Neurol. 2011, 68:51-57.
30. Watson G.S., Craft S. Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. Eur. J. Pharmacol. 2004, 490:97-113.
31. Schubert M., Gautam D., Surjo D., et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc. Natl. Acad. Sci. USA 2004, 101:3100-3105.
32. Bortz W.M. A conceptual framework of frailty: a review. J. Gerontol. A Biol. Sci. Med. Sci. 2002, 57:M283-288.
33. Raffaitin C., Gin H., Empana J.P., et al. Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study. Diabetes Care 2009, 32:169-174.